"Fluorine-18-labelled sodium fluoride (also known as 18F-NaF or sodium fluoride) is a PET radiotracer used primarily for skeletal imaging."
"The primary clinical use of sodium fluoride PET is in detection of osseous prostate cancer metastasis. It is FDA-approved for PET imaging in evaluation of metastatic bone disease and for evaluation of treatment response 2. However, its use has been largely replaced by 18F and 68Ga PSMA PET imaging, which offer superior sensitivity, particularly in patients with low PSA levels."
"The primary clinical use of sodium fluoride PET is in detection of osseous prostate cancer metastasis. It is FDA-approved for PET imaging in evaluation of metastatic bone disease and for evaluation of treatment response 2. However, its use has been largely replaced by 18F and 68Ga PSMA PET imaging, which offer superior sensitivity, particularly in patients with low PSA levels."
"Sodium fluoride PET has higher sensitivity and specificity in detecting and diagnosing bone diseases compared with conventional bone scintigraphy, even when the latter is supplemented with SPECT or SPECT/CT imaging 2."
"The primary clinical use of sodium fluoride PET is in detection of osseous prostate cancer metastasis. It is FDA-approved for PET imaging in evaluation of metastatic bone disease and for evaluation of treatment response 2. However, its use has been largely replaced by 18F and 68Ga PSMA PET imaging, which offer superior sensitivity, particularly in patients with low PSA levels."
"The primary clinical use of sodium fluoride PET is in detection of osseous prostate cancer metastasis. It is FDA-approved for PET imaging in evaluation of metastatic bone disease and for evaluation of treatment response 2. However, its use has been largely replaced by 18F and 68Ga PSMA PET imaging, which offer superior sensitivity, particularly in patients with low PSA levels."
"The primary clinical use of sodium fluoride PET is in detection of osseous prostate cancer metastasis. It is FDA-approved for PET imaging in evaluation of metastatic bone disease and for evaluation of treatment response 2. However, its use has been largely replaced by 18F and 68Ga PSMA PET imaging, which offer superior sensitivity, particularly in patients with low PSA levels."
Expected headings
"Structure"
"Distribution"
"Clinical uses"